Dossier
National Institute on Aging's Division of Aging Biology
Coverage of National Institute on Aging's Division of Aging Biology in the Nexus archive.
- Longevity medicine's do-or-die moment
The first human trial of an experimental gene therapy aims to test the safety of cellular reprogramming to rejuvenate aging cells, with initial focus on treating glaucoma. The trial, sponsored by Life Biosciences co-founded by David Sinclair, represents a critical step in validating the potential of epigenetic reprogramming to address age-related diseases.